Roche snags another Perjeta combo nod, but will 'weak' data limit its use?
admin 27th December 2017 Uncategorised 0Roche landed an end-of-the-year indication for Perjeta, but it’s an indication analysts and investors think may not be as lucrative as they once hoped.
More: Roche snags another Perjeta combo nod, but will 'weak' data limit its use?
Source: fierce